Tetratherix Ltd (TTX) - Total Assets
Based on the latest financial reports, Tetratherix Ltd (TTX) holds total assets worth AU$38.06 Million AUD (≈ $26.93 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of Tetratherix Ltd for net asset value and shareholders' equity analysis.
Tetratherix Ltd - Total Assets Trend (2023–2025)
This chart illustrates how Tetratherix Ltd's total assets have evolved over time, based on quarterly financial data.
Tetratherix Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Tetratherix Ltd's total assets of AU$38.06 Million consist of 97.1% current assets and 2.9% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 92.2% |
| Accounts Receivable | AU$0.00 | 0.0% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$885.91K | 2.8% |
| Intangible Assets | AU$41.04K | 0.1% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2023–2025)
This chart illustrates how Tetratherix Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Tetratherix Ltd market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tetratherix Ltd's current assets represent 97.1% of total assets in 2025, an increase from 66.4% in 2023.
- Cash Position: Cash and equivalents constituted 92.2% of total assets in 2025, up from 18.7% in 2023.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2023.
- Asset Diversification: The largest asset category is property, plant & equipment at 2.8% of total assets.
Tetratherix Ltd Competitors by Total Assets
Key competitors of Tetratherix Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Tetratherix Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.13 | 0.59 | 0.16 |
| Quick Ratio | 12.13 | 0.59 | 0.16 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$22.97 Million | AU$-6.82 Million | AU$-5.16 Million |
Tetratherix Ltd - Advanced Valuation Insights
This section examines the relationship between Tetratherix Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.04 |
| Latest Market Cap to Assets Ratio | 5.42 |
| Asset Growth Rate (YoY) | 2164.7% |
| Total Assets | AU$31.83 Million |
| Market Capitalization | $172.42 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Tetratherix Ltd's assets at a significant premium (5.42x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Tetratherix Ltd's assets grew by 2164.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Tetratherix Ltd (2023–2025)
The table below shows the annual total assets of Tetratherix Ltd from 2023 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$31.83 Million ≈ $22.52 Million |
+2164.74% |
| 2024-06-30 | AU$1.41 Million ≈ $994.56K |
+0.74% |
| 2023-06-30 | AU$1.40 Million ≈ $987.24K |
-- |
About Tetratherix Ltd
Tetratherix Limited engages in biomaterial and regenerative medicine business in Australia and internationally. The company manufactures and commercialize medical device in the areas of bone regeneration, tissue spacing, and tissue healing applications through its Tetramatrix platform technology. Tetratherix Limited was incorporated in 2015 and is based in Alexandria, Australia.